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Valvular Heart Disease
Increased Risk of Left Heart Valve Regurgitation Associated
With Benfluorex Use in Patients With Diabetes Mellitus
A Multicenter Study
Christophe Tribouilloy, MD, PhD; Dan Rusinaru, MD, PhD; Sylvestre Mare´chaux, MD, PhD;
Antoine Jeu, MD; Ste´phane Ederhy, MD; Erwan Donal, MD; Patricia Re´ant, MD;
Elise Arnalsteen, MD; Jacques Boulanger, MD; Pierre-Vladimir Ennezat, MD, PhD;
Thierry Garban, MD; Yannick Jobic, MD
Background—Benfluorex was withdrawn from European markets in June 2010 after reports of an association with heart
valve lesions. The link between benfluorex and valve regurgitations was based on small observational studies and
retrospective estimations. We therefore designed an echocardiography-based multicenter study to compare the
frequency of left heart valve regurgitations in diabetic patients exposed to benfluorex for at least 3 months and in
diabetic control subjects never exposed to the drug.
Methods and Results—This reader-blinded, controlled study conducted in 10 centers in France between February 2010 and
September 2011 prospectively included 376 diabetic subjects previously exposed to benfluorex who were referred by primary
care physicians for echocardiography and 376 diabetic control subjects. Through the use of propensity scores, 293 patients and
293 control subjects were matched for age, sex, body mass index, smoking, dyslipidemia, hypertension, and coronary artery
disease. The main outcome measure was the frequency of mild or greater left heart valve regurgitations. In the matched
sample, the frequency and relative risk (odds ratio) of mild or greater left heart valve regurgitations were significantly
increased in benfluorex patients compared with control subjects: 31.0% versus 12.9% (odds ratio, 3.55; 95% confidence
interval, 2.03–6.21) for aortic and/or mitral regurgitation, 19.8% versus 4.7% (odds ratio, 5.29; 95% confidence interval,
2.46–11.4) for aortic regurgitation, and 19.4% versus 9.6% (odds ratio, 2.38; 95% confidence interval, 1.27–4.45) for mitral
regurgitation.
Conclusions—Our results indicate that the use of benfluorex is associated with a significant increase in the frequency of
left heart valve regurgitations in diabetic patients. The natural history of benfluorex-induced valve abnormalities needs
further research. (Circulation. 2012;126:2852-2858.)
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Exposure to amphetamine-based appetite-suppressant drugssuch as fenfluramine and dexfenfluramine has been associ-
ated with life-threatening adverse effects as pulmonary hyper-
tension and cardiac valve regurgitations,1–3 leading to the with-
drawal of these drugs from the US market in 1997. Benfluorex,
an amphetamine derivative related to fenfluramine and dexfen-
fluramine in terms of structure, clinical effect, and metabolism
(hypoglycemic and hypolipidemic properties), has been pre-
scribed in Europe, Asia, and South Africa in patients with
hypertriglyceridemia and type II diabetes mellitus. It has also
been used off-label as a slimming aid.
Clinical Perspective on p 2858
Benfluorex was withdrawn from the European market in
2010 after the publication of several reports suggesting a link
between exposure to benfluorex and the occurrence of severe
valve regurgitations as previously observed with other fen-
fluramine derivatives.4–9 A case series reported 40 cases of
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moderate or severe valve regurgitation after exposure to
benfluorex.7 Patients in this report were highly symptomatic
and frequently had multiple valve abnormalities and pulmo-
nary arterial hypertension.7 Moreover, 2 case-control studies
have reported an important proportion of benfluorex use in
patients admitted to hospital for severe organic mitral regurgi-
tation of unclear origin.8,9 In a retrospective cohort study of 2
French national databases including a large number of patients
with diabetes mellitus, Weill et al10 observed a 3-fold increase in
the risk of hospitalization for valve regurgitation and a 4-fold
increase in the risk of valve replacement surgery in patients
exposed to benfluorex. According to recent estimations, expo-
sure to benfluorex might have been responsible for up to 3100
admissions to hospital for valvular heart disease and up to 1300
deaths resulting from valve regurgitations in France.11 These
data demonstrate that benfluorex has fenfluramine-like adverse
effects on valve structure and function and suggest excess
morbidity and mortality in exposed individuals.
However, previous studies were derived from hospital dis-
charge records and thus do not reflect the continuum of the
disease and have uncertain validity resulting from the selection
of the most severe forms of valve lesions and by shifts in coding
practices because of reimbursement incentives. Therefore, from
a population-based perspective, we lack prospective, controlled
data on the relationship between the exposure to benfluorex and
the risk of valve regurgitations. To address this issue, we
conducted an echocardiography-based multicenter study and
prospectively included a group of diabetic patients without
history of valve heart disease who had taken benfluorex for at
least 3 months and a matched group of diabetic patients who had
not taken this drug. Our aim was to compare the frequency of
left heart valve regurgitations in patients with diabetes mellitus
who had taken benfluorex and matched control subjects.
Methods
Study Design
The marketing authorization of benfluorex was suspended in France
in November 2009, and the French drug regulatory agency (Agence
franc¸aise de se´curite´ sanitaire des produits de sante´) issued a public
health advisory inviting all patients with previous exposure to
benfluorex to contact their primary care physician. Primary care
physicians further referred patients to a cardiologist for echocardi-
ography. On November 26, 2009, cardiology departments of all
French university hospitals, important private clinics, and general
hospitals were contacted by e-mail on behalf of the French Society
of Cardiology and invited to participate in this echocardiography
prospective multicenter study. Investigators (a complete list can be
found in the online-only Data Supplement) were asked to prospec-
tively enroll all consecutive diabetic patients without a history of
heart valve disease who were previously exposed to benfluorex and
referred by their primary care physicians for echocardiography.
Diabetes mellitus was defined as fasting glucose 126 mg/dL, use of
hypoglycemic agents, or a history of physician-diagnosed diabetes
mellitus. Ten centers participated in the present study (Centre
hospitalier universitaire d’Amiens, Centre hospitalier de Beauvais,
Centre hospitalier universitaire de Bordeaux, Centre hospitalier
universitaire de Brest, Centre hospitalier de Compie`gne, Centre
hospitalier universitaire de Lille, Groupe hospitalier de l’Institut
catholique de Lille, Centre hospitalier universitaire de Nantes,
AP-HP Hoˆpital Saint Antoine Paris, and Centre hospitalier univer-
sitaire de Rennes). This observational study was approved by the
ethics committee for noninterventional research at the University of
Picardie, Amiens, France. Oral consent was obtained for each
enrolled patient. Only 3 exposed patients referred by their primary
care physicians did not agree to participate.
Patients
All consenting benfluorex-treated patients referred by primary care
physicians for echocardiography to the participating centers were
enrolled in the present study if they had no history of heart valve
disease and if they had at least a previous 3-month exposure to
benfluorex since January 1, 2000. All patients were included after the
market withdrawal of the drug, starting February 1, 2010. It is worth
noting that all patients exposed to benfluorex who were referred for
a second expert evaluation after an initial echocardiography were not
included in the present study to avoid nonconsecutive enrollment that
might contribute to an overestimation of the frequency of valve
regurgitations. Patients who had been exposed to drugs that could
induce valvular heart diseases (rye ergot alkaloids, fenfluramine/
phentermine, dexfenfluramine, pergolide) were also excluded. Dur-
ing a 20-month period, 376 diabetic patients previously treated with
benfluorex were included. Demographic data, cardiovascular risk
factors, presence of symptoms, and echocardiography parameters
were recorded. Daily doses of benfluorex, and total duration of
treatment, were systematically and prospectively obtained before
echocardiography. Primary care physicians were contacted by phone
at the time of the echocardiography if there was doubt about
medications use or exposure time.
Control Subjects
During the same time period, 411 consecutive diabetic patients
without previous exposure to benfluorex or other drugs associated
with valve disease and without history of valve disease who were
referred by their primary care physicians to the outpatient diabetes
clinics of the participating centers were approached to participate. A
total of 376 patients consented and served as control subjects.
Collection of data was similar to that for patients treated with
benfluorex.
Echocardiography
Complete echocardiography examinations on commercially avail-
able ultrasound systems were performed in each center by experi-
enced operators according to a standardized protocol with multiple
2-dimensional incidences and use of different Doppler modes. When
possible, we obtained views of the mitral, aortic, tricuspid, and
pulmonary valves. To this effect, magnified video loops were
recorded in parasternal long-axis view for the aortic and mitral
valves; the parasternal short-axis view for the pulmonary, tricuspid,
and aortic valves; apical view for the tricuspid, mitral, and aortic
valves; and subcostal view for all valves when possible. All
recordings were obtained with and without Doppler color flow
mapping. Echocardiography examinations were stored in digital
DICOM (digital imaging and communications in medicine) format on
digital versatile disks for subsequent offline analysis. All echocardio-
grams were read independently by 2 cardiologists who were experts in
echocardiography and valvular heart diseases and were blinded to all
aspects of patient history, including benfluorex use. If there was
disagreement between the 2 readers, a third independent expert per-
formed a final blinded reading and gave the final grading. The severity
of valve regurgitations was expressed according to the recommenda-
tions of the European Society of Echocardiography (absence or trace,
mild, moderate, severe).12,13 The moderate regurgitation group was
subclassified into mild to moderate and moderate to severe.12,13 Stan-
dard 2-dimensional measurements (left ventricular end-diastolic and
end-systolic diameters) were obtained from the parasternal long-axis
views. Left atrium surface was calculated by planimetry from apical
4-chamber views. Left ventricular ejection fraction was calculated with
the Simpson biplane method. The maximal velocity of the tricuspid
regurgitation was estimated from continuous Doppler.
End Points
The primary echocardiography end point was mild or greater left
heart valve regurgitation (mitral and/or aortic). Secondary end points
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were mild or greater mitral regurgitation and mild or greater aortic
regurgitation.
Statistical Analysis
Quantitative data are presented as meanSD. Qualitative data are
presented as absolute numbers and percentages. Continuous data
were compared by use of the unpaired Student t test or the
Mann-Whitney U test in the case of highly skewed variables.
Categorical data were compared by use of the 2 test or Fisher exact
test as appropriate. Interreader variability was assessed with the 
statistic.
The imbalance in baseline variables between patients and control
subjects was reduced by the use of propensity scores. The propensity
scores for benfluorex exposure were estimated in each patient with a
multivariable logistic model in a forward stepwise regression anal-
ysis.14,15 The variables in the model were age, sex, body mass index,
smoking, dyslipidemia, hypertension, and coronary artery disease.
Goodness of fit, assessed by the Hosmer-Lemeshow test (29.3;
P0.56), and the discriminatory power of the model (area under the
receiver-operating characteristic curve, C0.71) were acceptable.
Propensity scores were used to match each patient to a unique control
subject with a propensity score within 2% through the use of a
greedy-matching algorithm that successively searched for matches
by 5, 4, 3, and 2 digits. In total, 293 pairs of patients (78%) were
successfully matched to individual control subjects within this
tolerance. Mean propensity score in patients before matching was
0.52719 compared with 0.462365 in control subjects (P0.001).
After matching, mean propensity score was 0.50023 in patients,
comparable to that of the control group (0.50017; P0.98). The
success of the propensity score matching was assessed by checking
standardized differences between groups after matching, ie, the
absolute difference in sample means divided by an estimate of the
pooled standard deviation of the variable expressed as a percentage.
Balancing was considered successful if the standardized differences
were 10%. The distributions of dichotomous variables between the
2 groups in the matched cohort were compared with the use of
McNemar tests. Continuous variables were compared between
groups in the matched cohort through the use of paired t tests or
Wilcoxon signed-rank tests as appropriate.
In the overall cohort, classic multivariable logistic regression
adjusted for age, sex, body mass index, smoking, dyslipidemia,
hypertension, and coronary artery disease was used to obtain
adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for
the outcome variables. For the matched cohort, OR estimates and
95% CIs for the outcome variables were produced from univariate
conditional logistic regression of each dichotomous variable on
benfluorex exposure, conditioning on the propensity-matched pairs.
All P values are the result of 2-tailed tests. For all tests, a value of
P0.05 was considered statistically significant. Statistical analysis
was performed with SPSS 13.0 (SPSS Inc, Chicago, IL) and STATA
version 10 (Stata Corp, College Station, TX).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
A total of 752 diabetic subjects (376 patients and 376 control
subjects) were enrolled during a 20-month period in the
participating centers. Characteristics used for propensity
matching are presented in Table 1 according to exposure to
benfluorex. Mean age was similar in patients and control
subjects. Compared with control subjects, benfluorex patients
were more frequently women, had greater body mass index,
and were more often dyslipidemia. In patients exposed to
benfluorex, mean dose was 352 mg (median, 450; range,
150–900 mg), and mean treatment duration 61.2 months
(median, 36.5 months; range, 3–360 months). After matching,
there were no statistically significant differences between the
293 benfluorex patients and the 293 control subjects in terms
of variables used for matching (all standardized differences
10%; Table 1). Duration since diagnosis of diabetes melli-
tus was 11.78.8 years in benfluorex patients and 11.68.9
years in control subjects (P0.88). Among benfluorex pa-
tients, 9.8% were on diet only, 83.2% were treated with 2
antidiabetic drugs, and 7.0% had 3 antidiabetic drugs. The
distribution of antidiabetic regimens was similar among
control subjects (10.1%, 83.8%, and 6.1%, respectively; all
P0.5). Cardiac murmurs were identified at the time of
echocardiography more frequently in patients exposed to
benfluorex compared with control subjects (8.5% versus
2.4%; P0.001 in the total cohort).
Left Heart Valve Regurgitation
In the overall population, the frequency of mild or greater aortic
and/or mitral regurgitation was 29.7% for benfluorex patients
and 13.6% for control subjects (P0.001). Mild aortic and/or
mitral regurgitation was observed in 22.3% of patients compared
with 12.8% of control subjects (P0.001; Table 2). Moderate
aortic and/or mitral regurgitation was also more frequent in
benfluorex patients compared with control subjects (7.4% versus
0.8%; P0.001; Table 2). There were no cases of severe aortic
and/or mitral regurgitation. The frequency of mild or greater
aortic and/or mitral regurgitation was still significantly higher in
patients exposed to benfluorex compared with control subjects
Table 1. Characteristics* of Patients Treated With Benfluorex and Control Subjects Before and After Matching
Variable











Age, y 63.610.8 65.612.0 0.26 63.010.0 64.012.0 0.98 9.05
Female sex, % (n) 49 (184) 43 (160) 0.08 46 (136) 45 (133) 0.80 2.01
Body mass index, kg/m2 31.55.5 29.45.7 0.001 30.44.9 30.35.5 0.90 1.90
Past or active smoker, % (n) 17 (63) 14 (54) 0.37 17 (50) 16 (47) 0.82 2.69
Dyslipidemia, % (n) 68 (254) 58 (218) 0.007 65 (189) 67 (197) 0.49 4.22
Hypertension, % (n) 68 (257) 67 (252) 0.70 68 (200) 69 (203) 0.86 2.15
Coronary artery disease, % (n) 14 (53) 19 (72) 0.06 16 (46) 17 (49) 0.82 2.69
Continuous variables are expressed as meanSD; dichotomous variables, as percentage and absolute number. Subjects treated with benfluorex and control
subjects were matched for age, sex, body mass index, smoking, dyslipidemia, hypertension, and coronary artery disease.
*Clinical variables used for matching.
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after the exclusion of patients with murmurs (25.0% versus
12.5%; P0.001), patients with overt (New York Heart Asso-
ciation class III or IV) symptoms (29.7% versus 13.5%;
P0.001), or both (29.6% versus 13.1%; P0.001). Among
patients exposed to benfluorex (median duration of treatment,
36.5 months), the frequency of left heart valve regurgitations
was greater in patients with treatment duration 36.5 months
compared with patients with a treatment duration 36.5 months
(35% versus 23.6%; P0.001). Classic multivariable logistic
regression showed increased risk of mild or greater left heart
valve regurgitation associated with exposure to benfluorex
(adjusted OR, 3.17; 95% CI, 2.05–4.87).
The frequency of mild or greater aortic and/or mitral
regurgitation in the matched sample was significantly higher
for benfluorex patients compared with control subjects
(31.0% versus 12.9%; P0.001). Mild and moderate aortic
regurgitation and/or mitral regurgitation were each individu-
ally more frequent in patients compared with control subjects
(Table 2). Univariate conditional logistic regression on the
matched pairs confirmed the risk of mild or greater aortic
and/or mitral regurgitation associated with benfluorex expo-
sure (OR, 3.55; 95% CI, 2.03–6.21). Two alternative ap-
proaches to adjustment for confounding, classic multiple
logistic regression and logistic regression modeling of the
matched cohorts with adjustment for the continuous propen-
sity score, basically yielded results similar to propensity-
based matched-pairs conditional logistic regression.
Adjustment for overt symptoms (class III/IV dyspnea) at
the time of echocardiography and the presence of a cardiac
murmur did not change the association between exposure to
benfluorex and the presence of mild or greater left heart valve
regurgitations (adjusted OR, 3.01; 95% CI, 1.98–4.68).
Aortic Regurgitation
In both the total and matched samples, the frequency of mild
or greater aortic regurgitation was higher in benfluorex
patients than in control subjects (20.0% versus 4.6% in the
total sample and 19.8% versus 4.7% in the matched sample;
both P0.001). This was due to a greater frequency of mild
and moderate aortic regurgitation in patients compared with
control subjects (Table 2). Among exposed patients with
moderate aortic regurgitation, 20 had mild to moderate
regurgitation and 1 patient had moderate to severe regurgita-
tion. The risk of mild or greater aortic regurgitation associated
with benfluorex exposure was increased 5-fold in both the
overall (adjusted OR, 5.21; 95% CI, 2.80–9.67) and matched
groups (OR, 5.29; 95% CI, 2.46–11.4). Exposure to benfluorex
was associated with an increased risk of moderate aortic regur-
gitation but also mild aortic regurgitation (Table 2).
Mitral Regurgitation
The frequency of mild or greater mitral regurgitation was
18.1% in the total sample and 19.4% in the matched sample
compared with 10.6%, and 9.6% in the control subjects (both
P0.001). Similar to aortic regurgitation, there was a greater
frequency of mild and moderate mitral regurgitation in
patients compared with control subjects (Table 2). Among
exposed patients with moderate mitral regurgitation, 6 had
Table 2. Frequency of Valvular Regurgitations According to the Degree of Severity in Patients Exposed to Benfluorex Compared With
Control Subjects Before and After Matching
Valvular
Regurgitations








(n293), % (n) OR† (95% CI) P
Aortic and/or mitral
regurgitation
None or trace 70.2 (264) 86.4 (325) Referent 68.9 (202) 87.0 (255) Referent
Mild 22.3 (84) 12.8 (48) 2.50 (1.66–3.78) 0.001‡ 24.2 (71) 12.6 (37) 2.35 (1.55–3.78) 0.001‡
Moderate 7.4 (28) 0.8 (3) 17.6 (5.10–61.1) 0.001‡ 6.8 (20) 0.3 (1) 20.0 (2.68–149.1) 0.003‡
Severe 0 (0) 0 (0) … 0 (0) 0 (0) …
Aortic regurgitation
None or trace 80.1 (301) 95.5 (359) Referent 80.2 (235) 95.2 (279) Referent
Mild 14.4 (54) 4.3 (16) 4.45 (2.44–8.13) 0.001‡ 15.4 (45) 4.4 (13) 4.20 (2.17–7.95) 0.001‡
Moderate 5.6 (21) 0.3 (1) 35.6 (4.59–230.3) 0.001‡ 4.4 (13) 0.3 (1) 14.8 (1.88–99.7) 0.013‡
Severe 0 (0) 0 (0) … 0 (0) 0 (0) …
Mitral regurgitation
None or trace 81.9 (308) 89.4 (336) Referent 80.5 (236) 90.4 (265) Referent
Mild 16.0 (60) 10.1 (38) 1.94 (1.23–3.08) 0.008‡ 16.7 (49) 9.6 (28) 1.92 (1.15–3.11) 0.014‡
Moderate 2.1 (8) 0.5 (2) 8.62 (1.63–45.6) 0.011‡ 2.7 (8) 0.0 (0) 5.62 (1.35–38.8) 0.02‡
Severe 0 (0) 0 (0) … 0 (0) 0 (0) …
Odds ratios reflect relative risk of mild and moderate regurgitations, respectively, compared to the group “none or trace” (referent).
OR indicate odds ratio; CI, confidence interval. Continuous variables are expressed as mean valueSD; dichotomous variables, as percentage and absolute number.
Relative risks of “mild or greater” valve regurgitations are not reported in this table but are detailed in the text.
*Odds ratios for valvular regurgitations associated with benfluorex exposure were estimated by logistic regression adjusted for age, sex, body mass index, smoking,
dyslipidemia, hypertension, and coronary artery disease.
†Odds ratios for valvular regurgitations associated with benfluorex exposure were estimated by propensity-based matched pairs univariate conditional logistic regression.
‡P values refer to comparisons of “mild” and “moderate” regurgitation, respectively to the group “none or trace” (referent).
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mild to moderate regurgitation and 2 had moderate to severe
regurgitation. The risk of mild or greater mitral regurgitation
associated with benfluorex exposure was increased 2-fold
in both the overall (adjusted OR, 2.34; 95% CI, 1.42–3.84)
and matched (OR, 2.38; 95% CI, 1.27–4.45) groups. Exposed
patients had increased risk of moderate mitral regurgitation
but also mild mitral regurgitation (Table 2).
Aortic and Mitral Regurgitation
The percentage of patients with combined mild or greater
aortic and mitral regurgitation mild was significantly higher
in benfluorex patients compared with control subjects (8.2%
versus 1.9% in the overall sample and 8.2% versus 1.7% in
the matched sample; both P0.001). The risk of combined
mild or greater aortic and mitral regurgitation associated with
benfluorex exposure was increased 5-fold in the overall
group (adjusted OR, 5.06; 95% CI, 2.15–11.9) and 4-fold
among the matched pairs (OR, 4.16; 95% CI, 1.56–11.2).
Reproducibility
The  coefficients for the interreader concordance in 3-level
categorizations (none or trace, mild, moderate) of regurgita-
tion were 0.80 for aortic regurgitation, 0.78 for mitral
regurgitation, and 0.81 for aortic and/or mitral regurgitation.
Other Clinical and Echocardiography Findings
In the overall cohort, at the time of echocardiography, patients
exposed to benfluorex more often had overt symptoms (12.2%
versus 7.4%; P0.028) and greater left ventricular ejection
fraction and left ventricular end-diastolic dimensions (Table 3).
The frequency of mild or greater tricuspid regurgitation was
10.5% in benfluorex patients and 8.1% in control subjects
(P0.21). The frequency of mild or greater pulmonary regurgi-
tation was also similar in patients and control subjects (7.9%
versus 8.7%; P0.93). After matching, overt symptoms were no
longer different between exposed patients and control subjects
(11.3% versus 8.5%; P0.11; Table 3).
Discussion
This is the first study to document an increased frequency of
left heart valve regurgitations among diabetic patients who
were treated with benfluorex compared with untreated dia-
betic subjects.
Several drugs have been incriminated in the development
of heart valve disease.16,17 Fenfluramine and dexfenfluramine
were withdrawn from the market in 1997 after reports
documenting increased risk of pulmonary hypertension18 and
heart valve regurgitation1,19,20 in patients treated with these
drugs. The main 2-dimensional echo feature of toxic heart
valve regurgitating lesions is “restriction,” ie, stiffening of
leaflets with retraction of leaflets or subvalvular apparatus
toward the apex (for the mitral valve) and opening/closure
with obvious doming of the leaflets (for the aortic valve).17
Benfluorex, a fenfluramine derivative prescribed in Europe
and Asia in patients with hyperlipidemia and diabetes melli-
tus but also widely used off-label as an appetite suppressant,
has recently been reported to have similar adverse effects on
heart valves. Like fenfluramine, benfluorex may exert a
serotoninergic effect via its metabolite, norfenfluramine.
Norfenfluramine has the capacity to activate the 5-HT(2B)
serotonin receptors in heart valves, which play a significant
role in the development of drug-induced fibrotic valvular
disease.16,17 The molecular mechanism is a G-protein–medi-
ated upregulation of transforming growth factor- that stim-
ulates mitogenic pathways and leads to increased production
of glycosaminoglycans and collagen.21,22
The risk of heart valve disease associated with exposure to
benfluorex was acknowledged after the recent publication of
data.4–11,23,24 The first case reports of valve disease and/or
pulmonary hypertension in patients exposed to benfluorex
were published between 2003 and 2010.4–6,23 Then, 40 cases
of moderate or severe valve disease associated with benfluo-
rex exposure were reported and analyzed.7 These cases
represent the most severe presentation of benfluorex-
associated valve disease and have quite homogeneous pre-
sentation: middle-aged patients, especially overweight
women, suffering from symptomatic heart failure caused by
significant aortic, mitral, or frequently multiple regurgitating
valve lesions.7 The high frequency of combined aortic and
mitral restrictive valve regurgitation associated with benfluo-
rex exposure was also observed by Boudes et al24 in a
single-center study of hospitalized patients with restrictive
valve disease. In a single-center case-control study, Frachon
et al8 reported high exposure to benfluorex among patients
hospitalized for mitral regurgitation of unclear origin (70%)
compared with patients with mitral regurgitation of known
origin (5.6%) and concluded that benfluorex was associated
with a high risk of mitral regurgitation. This finding was
confirmed by another case-control study showing that among
patients with mitral regurgitation of unclear origin, exposure
to benfluorex was identified in 40.9% of cases compared with










NYHA class III–IV dyspnea, % (n) 12.2 (46) 7.4 (28) 0.028 11.3 (33) 8.5 (25) 0.11
LV ejection fraction, % 62.87.3 61.27.7 0.008 62.57.4 61.67.2 0.01
LV end-diastolic diameter, mm 50.36.2 48.46.7 0.001 49.95.9 47.96.7 0.001
LV end-systolic diameter, mm 31.96.3 31.56.6 0.42 31.66.2 30.96.4 0.24
Left atrium surface, cm2 20.05.5 20.05.6 0.94 19.95.5 19.85.3 0.93
TR maximal velocity, m/s 2.450.36 2.410.41 0.18 2.450.38 2.390.39 0.13
LV indicates left ventricular; NYHA, New York Heart Association; and TR, tricuspid regurgitation. Continuous variables are expressed
as mean valueSD; dichotomous variables, as percentage and absolute number.
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4.5% in a matched group of patients with degenerative mitral
regurgitation resulting from flail leaflets.9
These series of observations were followed by retrospec-
tive cohort studies estimating of the risk of valvular damage,
hospitalizations, valve surgery, and death associated with
benfluorex exposure.10,11 The first cohort study by Weill et
al10 used the database of the French National System of
Reimbursement Information (Syste`me national d’information
inter re´gime de l’assurance maladie) and discharge diagnostic
data from public and private hospitalizations (Programme de
me´dicalisation des syste`mes d’informations) and analyzed
diabetic patients 40 to 69 years of age with reimbursements
for antidiabetic drugs in 2006. The authors reported a 3-fold
increase in the risk of hospital admission for mitral regurgi-
tation and a 4-fold increase in the risk of hospitalization for
aortic regurgitation and valvular replacement surgery during
the first 2 years after exposure to benfluorex.10 Finally,
according to a recent statistical estimation, use of benfluorex
between 1976 and 2009 in France would have been respon-
sible for 3100 admissions to hospital and 1300 deaths
resulting from valvular regurgitation.11
Our study demonstrates the association between benfluorex
exposure and increased frequency of left heart valve regurgita-
tions in prospectively included individuals with diabetes melli-
tus. In contrast to previous studies,10,11 the present study does not
use hospital discharge records and therefore is not biased by the
selection of the most severe forms of valve diseases and by
coding practices secondary to reimbursement issues. It is a
prospective multicenter study with a clear methodology and
careful echocardiography examination. Thus, we included con-
secutive diabetic outpatients previously exposed to benfluorex
who were referred for echocardiography by their general prac-
titioner. Moreover, by propensity matching, we obtained 2
groups that were balanced in terms of baseline characteristics.
Echocardiograms were read by 2 experts in echocardiography
who were blinded to the treatment status, and grading of
regurgitation was performed according to standard methods. We
report a 31% frequency of left heart valve regurgitations in
patients exposed to benfluorex compared with 13% in matched
control subjects. Previous exposure for at least 3 months to
benfluorex was associated in our study with a 3-fold increase
in the risk of mild or greater aortic and/or mitral valve regurgi-
tations, 5-fold increase in the risk of mild or greater aortic
regurgitation, and 2-fold increase in the risk of mild or greater
mitral regurgitation. The increased prevalence of left heart valve
regurgitations in patients exposed to benfluorex for at least 3
months was due mainly to an increased frequency of mild
regurgitations. The 3-month exposure period was chosen on the
basis of older fenfluramine/phentermine studies.2
In the fenfluramine/phentermine studies, the prevalence of
valve regurgitations varied considerably, ranging between 6%
and 30%, and the duration of treatment was associated with
development of clinical valvulopathy.17,25 In our study, we
observed an association between the duration of benfluorex
exposure and the frequency of regurgitations. As with fenflu-
ramine/phentermine, the risk of valve damage associated with
benfluorex appears to be more important for the aortic valve than
for the mitral valve. In the overall cohort, patients exposed to
benfluorex more often had overt symptoms, greater left ventric-
ular end-diastolic dimensions, and slightly higher left ventricular
ejection fraction, probably as a result of some amount of volume
overload. However, these findings probably cannot be explained
solely by a higher frequency of moderate regurgitations in
patients treated with benfluorex. Thus, after matching, the
frequency of overt symptoms was no longer different between
patients and control subjects. Mechanisms responsible for the
occurrence of class III/IV dyspnea in this population are prob-
ably multiple and are often noncardiac (eg, obesity and pulmo-
nary disease). There was no difference in left atrium size and
tricuspid regurgitation maximal velocity between patients and
control subjects, presumably because there were few subjects
with moderate regurgitations and no cases of severe
regurgitation.
The natural history of valve regurgitation after benfluorex
discontinuation is unknown. It has been reported that valve
regurgitations induced by fenfluramine have a variable natu-
ral history (regression, stabilization, or aggravation).3,25,26 A
prospective follow-up study of the natural history of
benfluorex-induced valve regurgitations in relation to sever-
ity at baseline is therefore needed.
Among patients exposed to benfluorex, we identified 2 cases
of moderate to severe mitral regurgitation and 1 case of moder-
ate to severe aortic regurgitation. We did not observe severe
valve regurgitations according to the criteria of the European
Society of Echocardiography.12,13 This is not surprising because
severe benfluorex-induced valve regurgitations appear to be
infrequent (1 per 1000 patient-years according to Weill et
al10). On the other hand patients included in the present study
were referred for echocardiography because of exposure to
benfluorex. Moreover, we excluded patients with previous
history of heart valve disease or referred for a second expert
echocardiography evaluation when an initial echocardiography
raised the suspicion of some kind of valvular abnormality.
Patients admitted to hospital for diagnostic workup of a valvular
lesion possibly induced by benfluorex were also excluded.
Therefore, the frequency of severe regurgitations was probably
underestimated. Thus, this study cannot establish the real fre-
quency of moderate and severe valve regurgitation induced by
benfluorex.
The present study should be considered in the context of
several limitations. It is not a randomized trial because benfluo-
rex was withdrawn from the market. It is not a prevalence study
because we excluded patients with previously suspected valve
disease and patients hospitalized for valve disease. The influence
of hidden or unmeasured covariates in the matching procedure
cannot be excluded. Restricting the study to diabetic patients has
allowed the formation of a more homogeneous study group and
has simplified the recruitment of control subjects. We acknowl-
edge that the method for selecting control subjects does not
entirely preclude differential selection bias, in addition to any
inherent confounding in the population. The study was con-
ducted after the patients took the drug, and there might have
been changes in valvular regurgitation in the period of time
between drug discontinuation and echocardiography. Echocar-
diograms were performed on different echocardiography ma-
chines, and Nyquist limit, gain, and persistence were not
standardized. The prevalence of valve regurgitations in a popu-
lation is highly variable, depending on the characteristics of the
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studied population and on the methods used to evaluate regur-
gitation. To the best of our knowledge, the prevalence of valve
regurgitations in diabetic subjects is unknown. Finally, our
results concern patients with diabetes mellitus and cannot be
extrapolated to the general population.
Conclusions
Our data show that diabetic patients exposed to benfluorex
have a significantly higher frequency of left heart valve
regurgitations compared with matched control subjects. The
risk associated with benfluorex use is greater for the aortic
valve. Further work is needed to establish the natural history
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CLINICAL PERSPECTIVE
The aim of this population-based multicenter study was to compare the frequency of left heart valve regurgitations
diagnosed by echocardiography in prospectively included diabetic patients who had taken benfluorex for at least 3 months
and in matched diabetic control subjects (matched for age, sex, body mass index, smoking, dyslipidemia, hypertension, and
coronary artery disease) without previous exposure to the drug. We found a significant increase in the frequency of mild
or greater left heart valve regurgitations among patients treated with benfluorex compared with propensity-matched control
subjects (31% vs. 13%; P0.001). Exposure to benfluorex was associated with a 3-fold increase in the risk of mild or
greater left heart valve regurgitations. Furthermore, the risk of benfluorex-induced regurgitations was more important for
the aortic valve compared with the mitral valve. Finally, the higher frequency of left heart valve regurgitations among
benfluorex-treated patients compared with control subjects was due mainly to an increased frequency of mild
regurgitations. The natural history of benfluorex-induced valve abnormalities needs further research.
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